NTRA Natera, Inc.
As of 11:21:00 AM ET
Loading chart…
- Open
- $417.72
- Previous close
- $414.30
- Day range
- 391.35 – 417.72
- 52-week range
- 181.00 – 437.41
- Volume
- 33.7K
- Avg volume (3M)
- 1.5M
- Market cap
- $61.2B
- P/E (TTM)
- −279.22
- EPS (TTM)
- −$1.35
- Beta
- 1.50
- Dividend yield
- 0.00%
- Next earnings
- —
- Ex-dividend
- —
- Sector
- Healthcare
About Natera, Inc.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 6, 2026(after close) | −$0.53 | −$0.47 | −11.3% |
| May 7, 2026(after close) | −$0.55 | −$0.60 | +9.1% |
| Feb 26, 2026(after close) | −$0.53 | $0.36 | −167.9% |
| Jan 23, 2026(after close) | $1.61 | $1.87 | +16.1% |
| Nov 6, 2025(after close) | −$0.35 | −$0.64 | +82.9% |
NTRA doesn’t pay a dividend.
NTRA news and filings
Loading filings…
Filings from SEC EDGAR.